Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466092 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL5465162 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL5465942 | 0.96 | ALDH1A1 (0.57) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL4878765 | 0.94 | KMT2A (0.51) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL4878759 | 0.94 | KMT2A (0.51) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL4881569 | 0.94 | KMT2A (0.51) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL5473768 | 0.93 | KMT2A (0.55) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL5473342 | 0.93 | KMT2A (0.55) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL5473335 | 0.93 | KMT2A (0.55) | ALDH1A1KMT2AMEN1OPRM1OPRL1 | |
| SCHEMBL5483337 | 0.91 | KMT2A (0.53) | ALDH1A1KMT2AMEN1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | ALDH1A1 2990/4885KMT2A 1301/4885MEN1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.